Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships MedinCell: development and commercialization of long-acting injectable products; Teva leads clinical development and regulatory process
Indications
Schizophrenia(Phase 3)
Status note Phase 3 completed. NDA submitted December 2025 (accepted February 2026); EMA MAA accepted May 2026.
ecopipam
Phase 3 · ActiveModality: small molecule
Aliases EBS-101
Target dopamine D1 receptor
Partnerships Emalex Biosciences: Teva acquired all outstanding shares June 2026 (~$700M); former shareholders eligible for milestones up to $200M plus royalties
Indications
Tourette syndrome (pediatric)(Phase 3)
Status note Phase 3 completed. NDA submitted to FDA June 18, 2026.
duvakitug
Phase 3 · ActiveModality: monoclonal antibody
Aliases TEV-574
Target TL1A
Partnerships Sanofi: collaboration (upfront $500M; $250M milestones per indication achieved Q4 2025); Sanofi leads Phase 3 development; 50/50 development cost and profit/loss share in major markets. Blackstone Life Sciences: up to $400M development funding
Indications
Ulcerative colitis(Phase 3)
Crohn's disease(Phase 3)
Hidradenitis suppurativa(Stage not disclosed)
Fibrostenotic Crohn's disease(Stage not disclosed)
Catalysts
— 2026
— 2026
Status note Phase 3 studies for ulcerative colitis and Crohn's disease initiated October 2025 by Sanofi and Teva.
emrusolmin
Phase 2 · Active
Aliases TEV-286
Partnerships Modag GmbH: exclusive global license to develop, manufacture and commercialize
Indications
Multiple System Atrophy (MSA)(Phase 2)
Parkinson's disease(Stage not disclosed)
Status note Phase 2 clinical trial for MSA initiated Q3 2024. FDA Fast Track designation for MSA (September 2025).
TEV-287
Phase 1 · Active
Partnerships Modag GmbH: collaboration
Indications
Parkinson's disease(Phase 1)
Status note Phase 1 clinical trial initiated Q2 2025.
TEV-408
Phase 1 · ActiveModality: monoclonal antibody
Target IL-15
Partnerships Royalty Pharma: funding agreement (up to $75M R&D funding; option for additional $425M based on Phase 2b results)
Indications
Vitiligo(Phase 1)
Celiac disease(Stage not disclosed)
Catalysts
— Q4 2026
Status note Phase 1b results completed; advancing to Phase 2b in vitiligo.
Partnerships Launch Therapeutics: clinical collaboration to accelerate the clinical research program. Abingworth: development funding
Indications
Asthma(Phase 3)
Status note Phase 3 trial ongoing; targeted initial enrollment levels in adult and pediatric populations achieved by end 2025.
BD9
Stage not disclosed · ActiveModality: multibody
Aliases TEV-325
Partnerships Biolojic Design: Teva received exclusive rights to develop, manufacture and globally commercialize
Indications
Asthma(Stage not disclosed)
Atopic dermatitis(Stage not disclosed)
Status note Early-stage multibody with potential indications including asthma and atopic dermatitis.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 12 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.